๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

The superiority of CCNU in the treatment of advanced hodgkin's disease: Cancer and leukemia group b study

โœ Scribed by Heine H. Hansen; Oleg S. Selawry; Thomas F. Pajak; Charles L. Spurr; Geoffrey Falkson; Kurt Brunner; Janet Cuttner; Nis I. Nissen; James F. Holland

Publisher
John Wiley and Sons
Year
1981
Tongue
English
Weight
382 KB
Volume
47
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Vinblastine in the treatment of advanced
Vinblastine in the treatment of advanced Hodgkin's disease
โœ Dr. W. Davies Sohier Jr.; Rose K. L. Wong; Alan C. Aisenberg ๐Ÿ“‚ Article ๐Ÿ“… 1968 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 470 KB ๐Ÿ‘ 2 views

In 35 cases of advanced Hodgkin's disease (stage IIIB to IVB), of whom 33 were no longer responsive to the alkylating agents, vinblastine produced clinically useful remissions in 22 patients or 64%. Complete objective responses were unusual but one third of these cases experienced partial remissions

Etoposide in combination as first-line c
Etoposide in combination as first-line chemotherapy for advanced Hodgkin disease. A cancer and leukemia group B study
โœ Jeffrey J. Kirshner; James R. Anderson; Barbara Parker; Maurice Barcos; M. Rober ๐Ÿ“‚ Article ๐Ÿ“… 1993 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 468 KB

Background. In a pilot study, Cancer and Leukemia Group B (CALGB) incorporated etoposide into primary combination therapy for advanced Hodgkin disease. Thirty-six evaluable patients were treated with two or three courses of methotrexate, vincristine, prednisone, leucovorin, etoposide, and cyclophos